Autonomous AI for diabetic retinopathy screening
The short answers is yes!
If you are curious about these questions then you should attend our upcoming webinar about autonomous AI in screening for diabetic retinopathy, based on fundus imaging.
Screening or frequent controls as in diabetic eye screening in the Nordic countries requires many resources for image acquisition and clinical grading - often with many normal exams without any disease or progression. With AI we will try to change this, for workload reduction and improved patient experience.
In this webinar, Chaithanya Ramachandra (Head of Research & Development at Eyenuk, Inc. ) will walk you through the current state and future of their EyeArt platform, being one of few autonomous AI solutions in healthcare, regulatory approved for autonomous AI grading in clinical use.
Register for this free webinar: https://www.dhirubhai.net/events/autonomouseyescreeningwithai7237376015117807617/
We will discuss the technology behind the solution, the potential impact on current practice, and the clinical evidence supporting the claims and regulatory approvals.
We will also unfold how the same AI can support detection of other eye diseases as AMD and Glaucoma, in the same workflow – and what the future brings in terms of enhanced quality, early detection and more personalized screening.
EyeArt is a medical device software, regulatory approved in EU (MDR class llB) and FDA approved in US. Eyeart is in live clinical use in EU and US and multiple other countries around the world.
About Human Bytes AI Academy
Our vision with the Human Bytes AI Academy is to bring new inspiration and perspectives for applied AI to healthcare. We will discuss myths, barriers and misunderstandings and invite some of the worlds' leading key opinion leaders to discuss specific use-cases.